close
MENU
Investment
7 mins to read

Fisher & Paykel Healthcare returns to pre-Covid growth trajectory

The company’s share price has risen as investors and analysts give the thumbs up to 2024 full-year results and outlook for FY25.

FPH managing director and CEO Lewis Gradon

Key points
  • Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
  • Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
  • Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.

It took 50 years for Fisher & Paykel Healthcare (FPH) to hit the milestone $1 billion revenue mark in 2019.

Five years later the respiratory healthcare company has given guidance of hitting close to double that – $1.9 billion to $2b in operating revenue for the 2025 financial year as growth rates

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual
Group membership
NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Fiona Rotherham Wed, 29 May 2024
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Key points
  • Revenue: FPH reported a 10% rise in revenue to $1.74 billion as growth returns to pre-Covid patterns.
  • Profit: Net profit after tax dropped 56% to $132.6 million after three abnormal items, while underlying profit rose 6% to $264.4m.
  • Key takeaway: The company is forecasting revenue for FY2025 of between $1.9 billion and $2 billion, net profit after tax of $310 million to $360m, and a lowered capital expenditure of around $150m. The assumption is based on a further improvement in gross margin based on historical pre-Covid levels.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Fisher & Paykel Healthcare returns to pre-Covid growth trajectory
Investment,
104274
true